Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Comment by Cgbuddyon Jan 22, 2021 1:10pm
189 Views
Post# 32360395

RE:RE:ITS A SCAM no revenu

RE:RE:ITS A SCAM no revenu
BillyKnowsBest wrote: lol, you don't get how biotechs start up do you?

Clinical trials come first, then FDA approval, then revenue can begin flowing

prices are based on clinical trial progression, development of future drug pipelines and the size of the market they are tackling

MMED has some of the best management in the game, and great progress with clinical trials including partnership with 2 major universities

They also have 2 former Directors of Jannsen Research (Johnson&Johnsons research division) running their clinical trials team. They have direct access to big pharma pipelines through these contacts and two people who have been dealing with the FDA for years, and understand what compliance takes

not to mention they disrupting a multi-billion dollar industry


Do some research, understand the industry, and look up who is investing in the space before you come and make irrelevant comments

good day to you sir



he prob try it shorter stuff that has worked in weed sector lol
<< Previous
Bullboard Posts
Next >>